New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia

References

• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi: 10.1182/blood-2011-01-293050
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. doi: 10.1053/sonc.2003.50082
   PubMed Web of Science ®Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
   PubMed Web of Science ®Google Scholar
• Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793–3800. doi: 10.1002/cncr.26627
   PubMed Web of Science ®Google Scholar
• Groves FD, Travis LB, Devesa SS, et al. Waldenström’s macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82(6):1078–1081. doi: 10.1002/(SICI)1097-0142(19980315)82:6<1078::AID-CNCR10>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459. doi: 10.3322/caac.21357
   PubMed Web of Science ®Google Scholar
• Buske C, Leblond V. How to manage Waldenstrom’s macroglobulinemia. Leukemia. 2013;27(4):762–772. doi: 10.1038/leu.2013.36
   PubMed Web of Science ®Google Scholar
• de Tute RM, Rawstron AC, Owen RG. Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells. Clin Lymphoma Myeloma Leuk. 2013;13(2):211–213. doi: 10.1016/j.clml.2013.02.018
   PubMed Web of Science ®Google Scholar
• Pasricha S-R, Juneja SK, Westerman DA, et al. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenström macroglobulinaemia. J Clin Pathol. 2011;64(6):520–523. doi: 10.1136/jcp.2010.088591
   PubMed Web of Science ®Google Scholar
• Menke MN, Feke GT, McMeel JW, et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):100–103. doi: 10.3816/CLM.2009.n.027
   PubMedGoogle Scholar
• Olszewski AJ, Treon SP, Castillo JJ. Evolution of management and outcomes in Waldenström macroglobulinemia: a population-based analysis. Oncologist. 2016;21(11):1377–1386. doi: 10.1634/theoncologist.2016-0126
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Eloranta S, Dickman PW, et al. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. Am J Hematol. 2013;88(1):60–65. doi: 10.1002/ajh.23351
   PubMed Web of Science ®Google Scholar
• Amaador K, Kersten MJ, Visser O, et al. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989–2018. Br J Haematol. 2022;196(3):660–669. doi: 10.1111/bjh.17856
   PubMed Web of Science ®Google Scholar
• Chien H-C, Morreall D, Patil V, et al. Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006–2019. Am J Hematol. 2021;96(6):E184–E187. doi: 10.1002/ajh.26133
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582. doi: 10.1046/j.1365-2141.2001.03144.x
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022–2035. doi: 10.1182/blood.2019000725
   PubMed Web of Science ®Google Scholar
• Vos JM, Gustine J, Rennke HG, et al. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016;175(4):623–630. doi: 10.1111/bjh.14279
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv41–iv50. doi: 10.1093/annonc/mdy146
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113(18):4163–4170. doi: 10.1182/blood-2008-08-174961
   PubMed Web of Science ®Google Scholar
• Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176. doi: 10.1111/bjh.12102
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenström macroglobulinaemia: a task force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016;175(1):77–86. doi: 10.1111/bjh.14196
   PubMed Web of Science ®Google Scholar
• Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96(3):852–858 doi:10.1182/blood.V96.3.852.
   PubMed Web of Science ®Google Scholar
• Leleu X, Xie W, Bagshaw M, et al. The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia. Clin Cancer Res. 2011;17(9):3013–3018. doi: 10.1158/1078-0432.CCR-10-2954
   PubMed Web of Science ®Google Scholar
• Greil C, Ihorst G, Gaiser F, et al. The serum heavy/light chain immunoassay: a valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. Eur J Haematol. 2017;99(5):449–458. doi: 10.1111/ejh.12958
   PubMed Web of Science ®Google Scholar
• Treon SP, Tedeschi A, San-Miguel J, et al. Report of consensus panel 4 from the 11th International Workshop on Waldenstrom’s Macroglobulinemia on diagnostic and response criteria. Semin Hematol. 2023;60(2):97–106. doi: 10.1053/j.seminhematol.2023.03.009
   PubMed Web of Science ®Google Scholar
• Pan Q, Cao X, Luo Y, et al. Baseline 18F-FDG PET/CT may portend the prognosis of patients with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma after first-line treatment. Clin Nucl Med. 2022;47(11):954–960. doi: 10.1097/RLU.0000000000004362
   PubMed Web of Science ®Google Scholar
• Banwait R, O’Regan K, Campigotto F, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011;86(7):567–572. doi: 10.1002/ajh.22044
   PubMed Web of Science ®Google Scholar
• Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):17–18. doi: 10.3816/CLM.2009.n.002
   PubMedGoogle Scholar
• Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenström macroglobulinemia: long-term results. Blood. 2012;119(19):4462–4466. doi: 10.1182/blood-2011-10-384768
   PubMed Web of Science ®Google Scholar
• Varettoni M, Zibellini S, Boveri E, et al. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. Br J Haematol. 2019;187(4):441–446. doi: 10.1111/bjh.16086
   PubMed Web of Science ®Google Scholar
• Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. doi: 10.1056/NEJMoa1709974
   PubMed Web of Science ®Google Scholar
• Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. J Clin Pathol. 2020;73(9):571–577. doi: 10.1136/jclinpath-2019-206282
   PubMed Web of Science ®Google Scholar
• Lemal R, Poulain S, Ledoux-Pilon A, et al. Mast cell density and its clinical relevance in Waldenström’s macroglobulinemia. EJHaem. 2022;3(2):371–378. doi: 10.1002/jha2.378
   PubMedGoogle Scholar
• Bassarova A, Trøen G, Spetalen S, et al. Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature. Am J Clin Pathol. 2015;143(6):797–806. doi: 10.1309/AJCP6ZODWV1CIDME
   PubMed Web of Science ®Google Scholar
• Amaador K, Vos JMI, Pals ST, et al. Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Leuk Lymphoma. 2022;63(5):1070–1079. doi: 10.1080/10428194.2021.2018584
   PubMed Web of Science ®Google Scholar
• Maqbool MG, Tam CS, Morison IM, et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology. 2020;52(2):167–178. doi: 10.1016/j.pathol.2019.11.002
   PubMed Web of Science ®Google Scholar
• Paiva B, Montes MC, García-Sanz R, et al. Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia. 2014;28(1):166–173. doi: 10.1038/leu.2013.124
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):187–195. doi: 10.1053/sonc.2003.50074
   PubMed Web of Science ®Google Scholar
• González D, van der Burg M, García-Sanz R, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110(9):3112–3121. doi: 10.1182/blood-2007-02-069625
   PubMed Web of Science ®Google Scholar
• Corbingi A, Innocenti I, Tomasso A, et al. Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 2020;190(6):901–908. doi: 10.1111/bjh.16975
   PubMed Web of Science ®Google Scholar
• Jelinek T, Bezdekova R, Zatopkova M, et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017;7(10):e617. doi: 10.1038/bcj.2017.90
   PubMedGoogle Scholar
• Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646. doi: 10.1182/blood-2013-09-525808
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 2013;98(4):649–654. doi: 10.3324/haematol.2012.070458
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Dogliotti I, Zaccaria GM, et al. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol. 2021;192(5):843–852. doi: 10.1111/bjh.17028
   PubMed Web of Science ®Google Scholar
• Paiva B, Corchete LA, Vidriales MB, et al. The cellular origin and malignant transformation of Waldenström macroglobulinemia. Blood. 2015;125(15):2370–2380. doi: 10.1182/blood-2014-09-602565
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198–1208. doi: 10.1200/JCO.19.02314
   PubMed Web of Science ®Google Scholar
• Askari E, Rodriguez S, Garcia-Sanz R. Waldenström’s macroglobulinemia: an exploration into the pathology and diagnosis of a complex B-cell malignancy. J Blood Med. 2021;12:795–807. doi: 10.2147/JBM.S267938
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021;138(20):1980–1985. doi: 10.1182/blood.2021011452
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. doi: 10.1056/NEJMoa1200710
   PubMed Web of Science ®Google Scholar
• Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia. 2013;27(8):1722–1728. doi: 10.1038/leu.2013.62
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121(22):4504–4511. doi: 10.1182/blood-2012-06-436329
   PubMed Web of Science ®Google Scholar
• Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–2528. doi: 10.1182/blood-2012-09-457101
   PubMed Web of Science ®Google Scholar
• Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–2058. doi: 10.1182/blood-2012-09-454355
   PubMed Web of Science ®Google Scholar
• Gustine J, Meid K, Xu L, et al. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström macroglobulinaemia. Br J Haematol. 2017;176(5):822–824. doi: 10.1111/bjh.13996
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström’s macroglobulinemia. N Engl J Med. 2015;373(6):584–586. doi: 10.1056/NEJMc1506192
   PubMed Web of Science ®Google Scholar
• Varettoni M, Zibellini S, Defrancesco I, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica. 2017;102(12):2077–2085. doi: 10.3324/haematol.2017.172718
   PubMed Web of Science ®Google Scholar
• Nakamura A, Ohwada C, Takeuchi M, et al. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS One. 2019;14(9):e0221941. doi: 10.1371/journal.pone.0221941
   PubMed Web of Science ®Google Scholar
• Mori N, Ohwashi M, Yoshinaga K, et al. L265P mutation of the MYD88 gene is frequent in Waldenström’s macroglobulinemia and its absence in myeloma. PLoS One. 2013;8(11):e80088. doi: 10.1371/journal.pone.0080088
   PubMed Web of Science ®Google Scholar
• Kim J-A, Im K, Park SN, et al. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia. Biomed Res Int. 2014;2014:363540. doi: 10.1155/2014/363540
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–119. doi: 10.1038/nature09671
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Hunter ZR, et al. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2018;180(4):578–581. doi: 10.1111/bjh.14386
   PubMed Web of Science ®Google Scholar
• Poulain S, Boyle EM, Roumier C, et al. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol. 2014;167(4):506–513. doi: 10.1111/bjh.13078
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018;180(3):374–380. doi: 10.1111/bjh.15049
   PubMed Web of Science ®Google Scholar
• Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic Waldenström macroglobulinemia. J Clin Oncol. 2019;37(16):1403–1411. doi: 10.1200/JCO.19.00394
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Paludo J, King RL, et al. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia. Am J Hematol. 2018;93(2):187–194. doi: 10.1002/ajh.24955
   PubMed Web of Science ®Google Scholar
• Zanwar S, Abeykoon JP, Durot E, et al. Impact of MYD88L265P mutation status on histological transformation of Waldenström macroglobulinemia. Am J Hematol. 2020;95(3):274–281. doi: 10.1002/ajh.25697
   PubMed Web of Science ®Google Scholar
• Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood. 2014;123(18):2791–2796. doi: 10.1182/blood-2014-01-550905
   PubMed Web of Science ®Google Scholar
• Wang Y, Gali VL, Xu-Monette ZY, et al. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. Neoplasia. 2021;23(4):361–374. doi: 10.1016/j.neo.2021.02.002
   PubMed Web of Science ®Google Scholar
• Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7(2):e112–e121. doi: 10.1016/S2352-3026(19)30210-8
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Garcia-Sanz R, Lee HP, et al. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020;4(23):6009–6018. doi: 10.1182/bloodadvances.2020003010
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Venet-Caillault A, et al. Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia. Clin Cancer Res. 2016;22(6):1480–1488. doi: 10.1158/1078-0432.CCR-15-0646
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s macroglobulinemia. Leukemia. 2015;29(1):169–176. doi: 10.1038/leu.2014.187
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019;184(6):1011–1014. doi: 10.1111/bjh.15200
   PubMed Web of Science ®Google Scholar
• Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2021;39(6):565–575. doi: 10.1200/JCO.20.00555
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–1440. doi: 10.1056/NEJMoa1501548
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241–250. doi: 10.1016/S1470-2045(16)30632-5
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol. 2018;36(27):2755–2761. doi: 10.1200/JCO.2018.78.6426
   PubMed Web of Science ®Google Scholar
• Tam CSL, Garcia-Sanz R, Opat S, et al. ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM). J Clin Oncol. 2022;40(16 suppl):7521. doi: 10.1200/JCO.2022.40.16_suppl.7521
   Web of Science ®Google Scholar
• Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019;186(1):146–149. doi: 10.1111/bjh.15718
   PubMed Web of Science ®Google Scholar
• Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, et al. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018;132(24):2608–2612. doi: 10.1182/blood-2018-07-863241
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström’s macroglobulinemia. Blood. 2014;124(4):503–510. doi: 10.1182/blood-2014-03-566273
   PubMed Web of Science ®Google Scholar
• Tomowiak C, Poulain S, Herbaux C, et al. Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Adv. 2021;5(9):2438–2446. doi: 10.1182/bloodadvances.2020003895
   PubMed Web of Science ®Google Scholar
• García-Sanz R, Jiménez C. Time to move to the single-cell level: applications of single-cell multi-omics to hematological malignancies and Waldenström’s macroglobulinemia—a particularly heterogeneous lymphoma. Cancers (Basel). 2021;13(7):1541. doi: 10.3390/cancers13071541.
   PubMed Web of Science ®Google Scholar
• Jiménez C, Prieto-Conde MI, García-Álvarez M, et al. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Ann Hematol. 2018;97(3):475–484. doi: 10.1007/s00277-017-3207-3
   PubMed Web of Science ®Google Scholar
• Gustine JN, Tsakmaklis N, Demos MG, et al. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019;184(2):242–245. doi: 10.1111/bjh.15560
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Bertrand E, et al. TP53 mutation and its prognostic significance in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2017;23(20):6325–6335. doi: 10.1158/1078-0432.CCR-17-0007
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33. doi: 10.1016/j.annonc.2020.09.019
   PubMed Web of Science ®Google Scholar
• Hunter ZR, Xu L, Yang G, et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016;128(6):827–838. doi: 10.1182/blood-2016-03-708263
   PubMed Web of Science ®Google Scholar
• Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037. doi: 10.1182/blood.2020006449
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–2050. doi: 10.1182/blood.2020006844
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Galiègue-Zouitina S, et al. Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. Am J Hematol. 2013;88(11):948–954. doi: 10.1002/ajh.23545
   PubMed Web of Science ®Google Scholar
• Jiménez C, Alonso-Álvarez S, Alcoceba M, et al. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. 2017;7(8):e591. doi: 10.1038/bcj.2017.72
   PubMed Web of Science ®Google Scholar
• Ntanasis-Stathopoulos I, Bagratuni T, Gavriatopoulou M, et al. Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. Am J Hematol. 2020;95(6):E148–E150. doi: 10.1002/ajh.25802
   PubMed Web of Science ®Google Scholar
• Wu Y-Y, Jia M-N, Cai H, et al. Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenström macroglobulinemia. Ann Hematol. 2020;99(8):1763–1769. doi: 10.1007/s00277-020-04139-7
   PubMed Web of Science ®Google Scholar
• Demos MG, Hunter ZR, Xu L, et al. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021;96(7):E250–E253. doi: 10.1002/ajh.26184
   PubMed Web of Science ®Google Scholar
• Drandi D, Genuardi E, Dogliotti I, et al. Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. Haematologica. 2018;103(6):1029–1037. doi: 10.3324/haematol.2017.186528
   PubMed Web of Science ®Google Scholar
• Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83(22):8604–8610. doi: 10.1021/ac202028g
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Celay J, Goicoechea I, et al. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma. Sci Adv. 2022;8(3):eabl4644. doi: 10.1126/sciadv.abl4644
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187(3):356–363. doi: 10.1111/bjh.16088
   PubMed Web of Science ®Google Scholar
• Kaiser LM, Hunter ZR, Treon SP, et al. CXCR4 in Waldenström’s macroglobulinema: chances and challenges. Leukemia. 2021;35(2):333–345. doi: 10.1038/s41375-020-01102-3
   PubMed Web of Science ®Google Scholar
• Campos-Martín Y, Martínez N, Martínez-López A, et al. Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma. Haematologica. 2017;102(8):e310–e312. doi: 10.3324/haematol.2016.161711
   PubMed Web of Science ®Google Scholar
• Gustine JN, Xu L, Yang G, et al. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4S338X by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021;194(4):730–733. doi: 10.1111/bjh.17385
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Varettoni M, Jiménez C, et al. Report of consensus panel 3 from the 11th International Workshop on Waldenström’s Macroglobulinemia: recommendations for molecular diagnosis in Waldenström’s macroglobulinemia. Semin Hematol. 2023;60(2):90–96. doi: 10.1053/j.seminhematol.2023.03.007.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378(25):2399–2410. doi: 10.1056/NEJMoa1802917
   PubMed Web of Science ®Google Scholar
• Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström’s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. J Clin Oncol. 2022;40(1):52–62. doi: 10.1200/JCO.21.00838
   PubMed Web of Science ®Google Scholar
• Kofides A, Hunter ZR, Xu L, et al. Diagnostic next-generation sequencing frequently fails to detect MYD88L265P in Waldenström macroglobulinemia. Hemasphere. 2021;5(8):e624. doi: 10.1097/HS9.0000000000000624
   PubMed Web of Science ®Google Scholar